Ciitizen Supercharges Its Patient Mission by Joining Forces With Invitae
We are excited today to announce that Ciitizen is being acquired by Invitae, an existing partner and leading precision medicine company, to further our mission of empowering patients with access to their medical data. Our team is thrilled about this next chapter and the opportunities it brings to better serve our patients. Thank you for your support of Ciitizen to date and your trust in our mission. Our patients are why we do what we do, and we look forward to the new ways we will be able to help you get more out of your health records.
Please click here to read the full statement from our founder, Anil.
Questions? Please see our FAQs below
Anil & the entire Ciitizen Team
Frequently Asked Questions
Ciitizen is being acquired by Invitae.
Leading genetic testing diagnostic company
Founded in 2010
Employee Count: Approx 2600
Countries: USA, Canada, Israel, Australia, Europe, LATAM, Asia
Corporation Status: Publicly traded: NVTA
About Invitae: https://www.Invitae.com/en/about
Mission: Invitae’s mission is to bring genetics to mainstream medicine to improve healthcare for billions. They believe all have the right to their full healthcare information and that the information becomes more valuable when it is made useful.
This is great news for the entire Ciitizen community! Since the passing of Anil’s sister Tania and our founding on September 11, 2017, dedicated patients, patient advocates, scientific advisors, partners and investors have been integral to the growth of Ciitizen’s patient-centric mission. Alongside our extraordinary community, we have built a company focused on helping patients take control of their health records and find the best treatment options. This announcement marks a continuation and expansion of this incredible work to drive better care for patients and accelerate research for better treatments and cures. Ciitizen and Invitae are joining forces to create the future of precision medicine through the integration of longitudinal clinical, genetic, and patient generated data, to create a truly patient-directed platform.
We have had tremendous success in creating a platform for patients with the cancer subtypes and rare neurological disorders that we are currently supporting, but we have always wanted Ciitizen to be available to all patients and their families. We chose to partner with Invitae because we are confident in our ability to build on our strong foundation with a like-minded partner that shares our core beliefs and values. With the importance of genetics as a key pillar of precision medicine, this partnership will allow us to scale our efforts and serve our patients and partners even more effectively.
We believe this partnership will allow us to accelerate our efforts to bring even more services to our patients and community. We will have access to many more resources to grow our team and serve you better, without compromising our core principles of privacy, patient-centricity and trust. Your healthcare data will have even more benefit to you and, should you consent, to research in pursuit of more cures.
Invitae and Ciitizen have signed and announced the acquisition and are finalizing the closing of the transaction, which is expected to take place within the month. Our goal is to make this transition as seamless as possible and there should be no impact on how we serve our patients and our partners.
Yes. Although Ciitizen will be a part of the Invitae group of companies, we will remain a separate team inside of Invitae, and we will keep the Ciitizen name for the foreseeable future.
There are no changes in our policies or in our mission. We chose to join forces with Invitae because of the alignment of mission and commitment to providing patients with full control of their health information in order to drive better personalized care and advance research for therapies and cures. Together, we will help more patients, faster. We are still Ciitizen, with our mission and strong commitment to putting patients first — but now as part of a bigger company that shares our goals and values, enabling us to serve our current users better and to grow to serve more patients.
No. Ciitizen users will continue to have control of the information in their records, and this information won’t be shared with third parties outside of Ciitizen and Invitae without a user’s consent. Period. The Ciitizen service and platform will continue to be free to individuals regardless of whether or not they share their health data. This combination will enable Ciitizen to move faster and offer the Ciitizen service to more patients.
Yes, our users will continue to have no-cost access to the platform.
Yes. You can always choose to close your Ciitizen account for any reason.
Yes. Please contact firstname.lastname@example.org with any questions about research or the status of your consent settings.
Invitae’s mission is to bring genetics to mainstream medicine. We believe this partnership will enable more access to genetic testing and other services for Ciitizen patients. While genetic testing may not be free, for some research opportunities, it is possible that users may be offered free or reduced cost genetic testing.
No. Research projects are not stopping and all in flight research will continue uninterrupted.
There are no planned changes to any ongoing research projects and will continue uninterrupted.
Your genetic results from Invitae will not be added to your Ciitizen profile unless you request and consent for this information to be added to your Ciitizen profile, no different than any other provider.
Ciitizen’s business model is to license research grade summary data created from your medical records, but only for patients who have consented to sharing their data for research purposes. Ciitizen users have the choice of whether or not to share their data for research and can keep their Ciitizen accounts – at no charge – even if they choose not to share their information with researchers.
Your data will still be protected by the same security protections as before Ciitizen became an Invitae company. Invitae shares our strong commitment to data security and has robust experience at protecting very sensitive genetic testing data.
Invitae is acquiring Ciitizen because of the success we have enjoyed to date – and a big reason for that success is the trust we have built with our users based on our strong privacy commitments. We don’t foresee those policies changing. But if there is a significant change in Ciitizen’s privacy policies or terms of service, Ciitizen – even as an Invitae company – would be required by law to tell you about these changes. You will have the option at that time to decide whether to continue to use Ciitizen or to close your account and have your data deleted.